Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors

Journal of Medicinal Chemistry

Volumn 48, Issue 23, 2005, Pages 7172-7185

  Manetti, Fabrizio ^a   Schenone, Silvia ^b   Bondavalli, Francesco ^b   Brullo, Chiara ^b   Bruno, Olga ^b   Ranise, Angelo ^b   Mosti, Luisa ^b   Menozzi, Giulia ^b   Fossa, Paola ^b   Trincavelli, Maria Letizia ^c   Martini, Claudia ^c   Martinelli, Adriano ^c   Tintori, Cristina ^a   Botta, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 AMINO 1 (2 CHLORO 2 PHENYLETHYL) 1H PYRAZOLO[3,4 B]PYRIDINE 5 CARBOXYLIC ACID DERIVATIVE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; CARTAZOLATE; ETAZOLATE; METHYL 1 (2 CHLORO 2 PHENYLETHYL) 4 [[2 (4 METHOXYPHENYL)ETHYL]AMINO] 1H PYRAZOLO[3,4 B]PYRIDINE 5 CARBOXYLATE; TRACAZOLATE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANIMALS; CATTLE; CEREBRAL CORTEX; HUMANS; MODELS, MOLECULAR; PYRAZOLES; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A3; RECEPTORS, ADENOSINE A2;

EID: 28544436111     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050407k     Document Type: Article

References (38)

1. Jacobson, K. A.; van Galen, P. J.; Williams, M. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J. Med. Chem. 1992, 35, 407-422.
2. Daly, J. W. Adenosine receptors: targets for future drugs. J. Med. Chem. 1982, 25, 197-207.
3. Collis, M. G.; Hourani, S. M. Adenosine receptor subtypes. Trends Pharmacol. Sci. 1993, 14, 360-363.
4. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998, 50, 413-492.
5. Poulsen, S. A.; Quinn, R. J. Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. 1998, 6, 619-641.
6. Müller, C. E.; Scior, T. Adenosine receptors and their modulators. Pharm. Acta Helv. 1993, 68, 77-111.
7. Müller, C. E.; Stein, B. Adenosine receptor antagonists: structures and potential therapeutic applications. Curr. Pharm. Des. 1996, 2, 501-530.
8. 1 adenosine receptor ligands. Curr. Top. Med. Chem. 2003, 3, 369-385.
9. Ribeiro, J. A.; Sebastião, A. M.; de Mendonça, A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 2002, 68, 377-392.
10. 1 adenosine receptors and their ligands: overview and recent developments. Farmaco 2001, 56, 77-80.
11. 2A adenosine receptors. Bioorg. Med. Chem. 2000, 8, 2581-2590.
12. 1 receptor antagonist as diuretic. Cardiovasc. Drug Rev. 1997, 775, 44-58.
13. 2-adenosine receptors. Biochem. Pharmacol. 1988, 37, 655-664.
14. 2 adenosine receptors. Med. Chem. Res. 1994, 4, 293-306.
15. (a) Akane, A.; Kuroda, S.; Itani, H.; Shimizu, Y. Patent NO W09803507, 1998; Chem. Abstr. 1998, 128, 154090.
16. (b) Akane, A.; Nishimura, S.; Kuroda, S.; Itani, H. Patent NO JP10182643, 1998; Chem. Abstr. 1998, 729, 144876.
17. 1AR) ligands. Bioorg. Med. Chem. Lett. 2001, 77, 2529-2531.
18. 1 receptor antagonists. J. Med. Chem. 2002,45,4875-4887.
19. Schenone, S.; Bruno, O.; Bondavalli, F.; Ranise, A.; Mosti, L.; Menozzi, G.; Fossa, P.; Manetti, F.; Morbidelli, L.; Trincavelli, L.; Martini, C.; Lucacchini, A. Synthesis of 1-(2-chloro-2-phen-ylethyl)-6-methylthio-lH- pyrazolo[3,4-d]pyrimidines 4-amino substituted and their biological evaluation. Eur. J. Med. Chem. 2004, 39, 153-160.
20. 1 adenosine receptor antagonists. J. Med. Chem. 2001, 44, 316-327.
21. 4-Amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5- carboxylic acid ethyl ester derivatives as reported in ref 16 (1a-If) and 1-(2-chloro-2-phenylethyl)-6-methylthio-1H-pyrazolo [3,4-d]pyrimidines-4-amino substituted as reported in ref 18 (77-80).
22. 1,8-Naphthyridine as reported in ref 30 (15-44); 1,2,4-triazolo-[4,3-a] quinoxalin-1-ones as reported in ref 31 (45-60); 3-aryl-[1,2,4] triazino[4,3-a]benzimidazol-4(10H)-ones as reported in ref 19 (61-76).
23. i > 10 μM couldbe reported, similarly to that described for compounds 37 and 38 (ref 30). However, both cases describe inactive compounds. As a consequence, on the basis of the fact that also inactive compounds could be a source of important structural information for qualitative and quantitative structure-activity relashionship analysis, we (i. Corelli, F.; Manetti, F.; Tafi, A.; Campiani, G.; Nacci, V.; Botta, M. Diltiazem-like calcium entry blockers: a hypothesis of the receptor-binding site based on a comparative molecular field analysis model. J. Med. Chem. 1997, 40, 125-131; ii.)
24. Tafi, A.; Anastassopoulou, J.; Theophanides, T.; Botta, M.; Corelli, F.; Massa, S.; Artico, M.; Costi, R.; Di Santo, R.; Ragno, R. Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study. J. Med. Chem. 1996, 39, 1227-1235)
25. and others (L Ragno, R.; Artico, M.; De Martino, G.; La Regina, G.; Coluccia, A.; Di Pasquali, A.; Silvestri, R. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase nonnucleoside binding site and design of highly active JV-(2-hydroxyethyl)-carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives. J. Med. Chem. 2005, 48, 213-223; ii.
26. i = 5.0), and also corresponding to the maximum concentration of each ligand tested (10 μM).
27. Nielsen, E. O.; Audouze, K.; Peters, D. New series of morpholine and 1,4-oxazepane derivatives as dopamine D4 receptor ligands: synthesis and 3D-QSAR model. J. Med. Chem. 2004, 47, 3089-3104.
28. GOLPE 4.5.12; Multivariate Infometric Analyses: Viale dei Castagni, 16 Perugia, Italy, 1999.
29. GRID 21; Molecular Discovery Ltd, 215 Marsh Road, Pinner, Middlesex, UK.
30. Catalyst 4.9, Accelrys, Inc., San Diego, CA, 2003.
31. Marshall G. R., Barry, C. D.; Bosshard, H. E.; Dammkoehler, R. A.; Dunn, D. A. The conformational parameter in drug design: the active analog approach. In Computer-Assisted Drug Design, Olson, E. C., Christoffersen, R. E., Eds.; American Chemical Society: Washington, DC, 1979; Vol. 112, pp 205-226.
32. 2, Version 4.8; Accelrys Inc., San Diego, CA, 2003.
33. i) was estimated to be 9.6, in good agreement with the experimental value of 10.2. Alignment of such a compound in the current pharmacophoric model (Figure 2) shows HY1-3 filled by the propyl chain at positions 1 and 3 and by the cyclopentyl ring, respectively. Moreover, the 6- and 2-carbonyl groups are HBA1 and HBA2, respectively, while HBD is the 1-NH group.
34. Ferrarini, P. L.; Betti, L.; Cavallini, T.; Gianaccini, G.; Lucacchini, A.; Manera, C.; Martinelli, A.; Ortore, G.; Saccomanni, G.; Tuccinardi, T. Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J. Med. Chem. 2004, 47, 3019-3031.
35. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-clquinoline derivatives as adenosine receptor antagonists. J. Med. Chem. 2000, 43, 3118-3124.
36. Pirovano, I. M.; IJzerman, A. P.; van Galen, P. J. M.; Soudijn, W. The influence of molecular structure of N6-(aminoalkyl)-adenosines on adenosine receptor affinity and intrinsic activity. Eur. J. Pharmacol. 1989, 172, 185-193.
37. Catarzi, D.; Colotta, V.; Varano, F.; Calabri, F. R.; Lenzi, O.; Filacchioni, G.; Trincavelli, M. L.; Martini, C.; Tralli, A.; Montopoli, C.; Moro, S. 2-Aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists. Bioorg. Med. Chem. 2005, 13, 705-15.
38. 50) of an enzyme reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.